HLA-A2 Mesenchymal Stem Cell Composition for Inflammation Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mesenchymal stem cells used for treating inflammation have adverse effects and limited efficacy, particularly those not expressing HLA-A2, which are less effective in inhibiting inflammatory cytokines and promoting anti-inflammatory markers.
Innovation Solution
A pharmaceutical composition utilizing mesenchymal stem cells expressing HLA-A2 at a level of 70% or higher, characterized by specific surface markers, is developed to inhibit inflammation by reducing TNF-α secretion and increasing CD163 and Arg-1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressants or steroids are used to treat inflammation, then anti-inflammatory effect is achieved, but adverse effects increase and disease relapse occurs upon discontinuation
Solution Approach 1:
The patent extracts and utilizes specific surface markers (HLA-A2, CD73, CD90, CD105, CD166) from mesenchymal stem cells to identify and isolate a cell population with superior anti-inflammatory properties. This extraction of key identifying features enables selection of cells that provide therapeutic effects without the adverse effects of conventional drugs.
Solution Approach 2:
The patent changes the selection parameter for mesenchymal stem cells from generic criteria to specific surface marker expression levels (HLA-A2≥70%, CD73≥70%, CD90≥70%, CD105≥70%, CD166≥70%). This parameter change identifies a cell subset with enhanced anti-inflammatory efficacy and reduced adverse effects compared to conventional treatments.
2Reliability
If mesenchymal stem cells not expressing HLA-A2 are used for inflammation treatment, then cell therapy is provided, but anti-inflammatory efficacy is limited
Solution Approach 1:
The patent applies local quality by focusing on specific surface marker expression (HLA-A2, CD73, CD90, CD105, CD166) as distinguishing features of mesenchymal stem cells. By selecting cells with high expression of these specific markers, the patent identifies a population with enhanced local anti-inflammatory activity, particularly in suppressing TNF-α and inducing CD163 and Arg-1.
Solution Approach 2:
The patent changes the selection criterion from general mesenchymal stem cell characteristics to specific surface marker expression thresholds (HLA-A2≥70%, CD73≥70%, CD90≥70%, CD105≥70%, CD166≥70%). This parameter change selects for a cell population with superior productivity in terms of inflammatory cytokine inhibition and anti-inflammatory marker promotion.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to a pharmaceutical composition comprising HLA-A2-expressing mesenchymal stem cells as an effective ingredient for prevention or treatment of inflammatory disease. According to the present invention, the mesenchymal stem cells expressing HLA-A2 on the surface thereof inhibit the secretion of the inflammatory cytokine TNF-a and increase the expression of the anti-inflammatory markers CD163 and Arg-1, so that the pharmaceutical composition comprising the mesenchymal stem cells as an effective ingredient can be advantageously used for suppressing inflammation or treating inflammatory diseases.